Magnera Price Target Cut to $12, Rating Downgraded to Equal Weight
Magnera was downgraded from Overweight to Equal Weight and saw its price target slashed from $19 to $12 as Wells Fargo flagged concerns over the company’s leverage, U.S. revenue concentration and production exposure. The firm cited defensive positioning needs given current sector volatility and leverage risks.
1. Downgrade Details
Wells Fargo downgraded Magnera’s rating from Overweight to Equal Weight and cut the price target to $12 from $19, marking a significant reduction in expected upside.
2. Rationale and Market Context
The firm cited Magnera’s relatively high leverage, concentrated U.S. exposure and production risks, noting that companies with lower leverage and more defensive operations are better positioned amid current sector volatility.
Related News
MRNA
Moderna Underweight with $40 December 2026 Price Target
MRNA•
MOB
Mobilicom Lands Two U.S. Defense Drone Design Wins, Schedules May 27 Q1 Results
MOB•
NVDL
GraniteShares 2x Daily Nvidia ETF Gains 172%, Tops $4 Billion AUM
NVDL•
MDLN
Medline Debuts Spay/Neuter Surgical Packs to Boost Veterinary Efficiency
MDLN•
QQQ
Nasdaq-100 ETF Trackers Eye 30% EM Earnings Growth and Nvidia’s $78.8B Quarter
QQQ•
Sources
F